About Me

Me_01 (2)

A medical biochemistry generalist with over 20 years of research experience discovering and developing new medicines. My efforts have helped expand the medical knowledge-base through peer-reviewed publications and patents. Originally starting out in industry, I found a niche in academia teaching trainees how to be good scientists. I want to continue to use these skills to help communicate high-quality medical science information.

Education

Ph.D. Biochemistry
University of Toronto, Faculty of Medicine 1993 – 1998

B.Sc. Biochemistry Specialist (Honours) 
University of Toronto, Faculty of Arts and Science 1989 – 1993

Research

University Health Network 2003 – 2016   Research Associate 

  • Managed biochemistry research lab and X-ray diffraction facilities
  • Trained postdocs, graduate, and undergraduate students
  • Structural and functional strudies on enzymes and antibodies

GlycoDesign Inc. 2000 – 2003   Research Scientist

  • HTS and advanced enzyme kinetics on glycobiological drug targets

Apotex Research Inc. 1998 – 2000   Research Scientist

  • Advanced enzyme kinetics on thiol-based drug targets

Publications

The mechanism of GM-CSF inhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities (2018) MAbs doi: 10.1080/19420862.2018.1494107 (Epub ahead of print). U Dhagat, TR Hercus, SE Broughton, TL Nero, KS Cheung Tung Shing, EF Barry, CA Thomson, S Bryson, EF Pai, BJ McClure, JW Schrader, AF Lopez, MW Parker

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma (2018) ChemMedChem13(9): 957-967. R De Gasparo, E Brodbeck-Persch, S Bryson, NB Hentzen, M Kaiser, EF Pai, RL Krauth-Siegel, F Diederich

Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation (2016) J Immunol196: 4723-30. S Bryson, CA Thomson, LF Risnes, S Dasgupta, K Smith, JW Schrader, EF Pai

Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity (2016) J Med Chem59: 624-46. JD Goodreid, J Janetzko, JP Jr Santa Maria, KS Wong, E Leung, BT Eger, S Bryson, EF Pai, SD Gray-Owen, S Walker, WA Houry, RA Batey

Binding to Large Enzyme Pockets: Small-Molecule Inhibitors of Trypanothione Reductase (2014) ChemMedChem9(8): 1880-91. E Persch, S Bryson, NK Todoroff, C Eberle, J Thelemann, N Dirdjaja, M Kaiser, M Weber, H Derbani, R Brun, G Schneider, EF Pai, RL Krauth-Siegel, F Diederich

Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design (2014) J Biol Chem289: 6565-80. S Serrano, A Araujo, B Apellániz, S Bryson, P Carravilla, I de la Arada, N Huarte, E Rujas, EF Pai, JL Arrondo, C Domene, MA Jiménez, JL Nieva

Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope (2012) J Mol Biol41: 175-92. ML Azoitei, YE Ban, JP Julien, S Bryson, A Schroeter, O Kalyuzhniy, JR Porter, Y Adachi, D Baker, EF Pai, WR Schief

Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications (2009) J Virol83: 11862-75. S Bryson, JP Julien, RC Hynes, EF Pai

Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site (2008) J Mol Biol384: 377-92. JP Julien, S Bryson, JL Nieva, EF Pai

Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus (2008) EMBO J27: 2592-602. CA Thomson, S Bryson, GR McLean, AL Creagh, EF Pai, JW Schrader

Crystal structure of the complex between the F(ab) fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6 (2008) J Mol Biol382: 910-9. S Bryson, JP Julien, DE Isenman, R Kunert, H Katinger, EF Pai

A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity (2005) Mol Immunol42: 1111-9. GR McLean, M Torres, B Trotter, M Noseda, S Bryson, EF Pai, JW Schrader, A Casadevall

Highly conserved cysteines of mouse core 2 beta1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity (2003) J Biol Chem278: 45864-81. TY Yen, BA Macher, S Bryson, X Chang, I Tvaroska, R Tse, S Takeshita, AM Lew, A Datti 

Patent

Thiadiazole Compounds Useful as Inhibitors of Cysteine Activity Dependent Enzymes (2001) WO0190095. K Karimian, TF Tam, R Leung-Toung, W Li, S Bryson, and JM Wodzinska

Me_01 (2)

A medical biochemistry generalist with over 20 years of experience, I’ve been fortunate to conduct research into the discovery of new medicines. My efforts have helped expand the medical knowledge-base through peer-reviewed publications and patents. Originally starting out in industry, I found a niche in academia teaching trainees how to be good scientists. I want to continue to use these skills to educate and communicate high quality medical science information.

Check out my CV below…

Education

Ph.D. Biochemistry
University of Toronto, Faculty of Medicine 1993 – 1998

B.Sc. Biochemistry Specialist (Honours) 
University of Toronto, Faculty of Arts and Science 1989 – 1993

Research

University Health Network 2003 – 2016  Research Associate 

  • Managed biochemistry research lab and X-ray diffraction facilities
  • Trained postdocs, graduate, and undergraduate students
  • Structural and functional strudies on enzymes and antibodies

GlycoDesign Inc. 2000 – 2003  Research Scientist

  • THS and advanced enzyme kinetics on glycobiological drug targets

Apotex Research Inc. 1998 – 2000  Research Scientist

  • Advanced enzyme kinetics on thiol-based drug targets

Publications

The mechanism of GM-CSF ainhibition by human GM-CSF auto-antibodies suggests novel therapeutic opportunities (2018) MAbs doi: 10.1080/19420862.2018.1494107 (Epub ahead of print). U Dhagat, TR Hercus, SE Broughton, TL Nero, KS Cheung Tung Shing, EF Barry, CA Thomson, S Bryson, EF Pai, BJ McClure, JW Schrader, AF Lopez, MW Parker

Biological Evaluation and X-ray Co-crystal Structures of Cyclohexylpyrrolidine Ligands for Trypanothione Reductase, an Enzyme from the Redox Metabolism of Trypanosoma (2018) ChemMedChem13(9): 957-967. R De Gasparo, E Brodbeck-Persch, S Bryson, NB Hentzen, M Kaiser, EF Pai, RL Krauth-Siegel, F Diederich

Structures of Preferred Human IgV Genes-Based Protective Antibodies Identify How Conserved Residues Contact Diverse Antigens and Assign Source of Specificity to CDR3 Loop Variation (2016) J Immunol196: 4723-30. S Bryson, CA Thomson, LF Risnes, S Dasgupta, K Smith, JW Schrader, EF Pai

Development and Characterization of Potent Cyclic Acyldepsipeptide Analogues with Increased Antimicrobial Activity (2016) J Med Chem59: 624-46. JD Goodreid, J Janetzko, JP Jr Santa Maria, KS Wong, E Leung, BT Eger, S Bryson, EF Pai, SD Gray-Owen, S Walker, WA Houry, RA Batey

Binding to Large Enzyme Pockets: Small-Molecule Inhibitors of Trypanothione Reductase (2014) ChemMedChem9(8): 1880-91. E Persch, S Bryson, NK Todoroff, C Eberle, J Thelemann, N Dirdjaja, M Kaiser, M Weber, H Derbani, R Brun, G Schneider, EF Pai, RL Krauth-Siegel, F Diederich

Structure and immunogenicity of a peptide vaccine, including the complete HIV-1 gp41 2F5 epitope: implications for antibody recognition mechanism and immunogen design (2014) J Biol Chem289: 6565-80. S Serrano, A Araujo, B Apellániz, S Bryson, P Carravilla, I de la Arada, N Huarte, E Rujas, EF Pai, JL Arrondo, C Domene, MA Jiménez, JL Nieva

Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope (2012) J Mol Biol41: 175-92. ML Azoitei, YE Ban, JP Julien, S Bryson, A Schroeter, O Kalyuzhniy, JR Porter, Y Adachi, D Baker, EF Pai, WR Schief

Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications (2009) J Virol83: 11862-75. S Bryson, JP Julien, RC Hynes, EF Pai

Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site (2008) J Mol Biol384: 377-92. JP Julien, S Bryson, JL Nieva, EF Pai

Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus (2008) EMBO J27: 2592-602. CA Thomson, S Bryson, GR McLean, AL Creagh, EF Pai, JW Schrader

Crystal structure of the complex between the F(ab) fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6 (2008) J Mol Biol382: 910-9. S Bryson, JP Julien, DE Isenman, R Kunert, H Katinger, EF Pai

A point mutation in the Ch3 domain of human IgG3 inhibits antibody secretion without affecting antigen specificity (2005) Mol Immunol42: 1111-9. GR McLean, M Torres, B Trotter, M Noseda, S Bryson, EF Pai, JW Schrader, A Casadevall

Highly conserved cysteines of mouse core 2 beta1,6-N-acetylglucosaminyltransferase I form a network of disulfide bonds and include a thiol that affects enzyme activity (2003) J Biol Chem278: 45864-81. TY Yen, BA Macher, S Bryson, X Chang, I Tvaroska, R Tse, S Takeshita, AM Lew, A Datti 

 

Patent

Thiadiazole Compounds Useful as Inhibitors of Cysteine Activity Dependent Enzymes (2001) WO0190095. K Karimian, TF Tam, R Leung-Toung, W Li, S Bryson, and JM Wodzinska

Close Menu